secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001140361-22-039875
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma Q3 net loss $57.8M; cash $306.5M; Renovacor acquisition, LAD-I/FA filings on track
--------------------------------------------------------------------------------

- Net loss $57.8M ($0.87/sh) vs $50.1M in Q3 2021; R&D expenses $43.4M, G&A $15.1M.
- Cash, equivalents and investments $306.5M; after $108.2M equity offering, operational runway into 2H 2024.
- Announced all-stock acquisition of Renovacor (implied ~$2.60/sh) to extend AAV cardiac gene therapy; expected close Q1 2023.
- Danon Disease Phase 1 data positive; FDA feedback on Phase 2 pivotal design anticipated Q4 2022.
- LAD-I regulatory filing expected 1H 2023, FA filing 2H 2023; PKD Phase 1 enrollment complete, Phase 2 pivotal in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036122039875/0001140361-22-039875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036122039875/brhc10043730_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-039875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer